Madrigal Pharmaceuticals Inc (NAS:MDGL)
$ 235.97 -8.38 (-3.43%) Market Cap: 5.03 Bil Enterprise Value: 4.27 Bil PE Ratio: 0 PB Ratio: 5.74 GF Score: 44/100
Back to the Transcripts List

Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 02:30PM GMT
Release Date Price: $292.21 (+0.66%)
Unidentified Analyst

Good morning, everybody, and thanks for joining day two of the JMP Life Science Conference. My name is John Walden. I'm pleased to have the team from Madrigal Pharmaceuticals joining us Rebecca Taub, CMO; CEO, Paul Friedman; and Chief Commercial Officer, Remy Sukhija. Thanks for joining us today, guys. I think everybody is familiar with the Madrigal story by now and the unmet need in NASH. But maybe to start, can we talk about the master of NASH data and the key learnings and then what that means moving forward for you guys?

Rebecca Taub
Madrigal Pharmaceuticals, Inc. - Director, Founder, Chief Medical Officer and President of Research & Development

Yeah. So as you know, we announced data the December of 42, and we have an update in January of 23 where we achieve both liver biopsy primary endpoints of the study, which was it's a 54-month study in overall, but there was a 52-week serial liver biopsy endpoint and about 1,000 patients. And we showed that resmetirom had both daily doses, 80 and 100 milligrams achieved the primary endpoints which

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.